StockNews.AI
MTVA
StockNews.AI
118 days

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

1. MetaVia announces Phase 2a trial data presentation for DA-1241 at EASL 2025. 2. DA-1241 shows hepatoprotective effects and improves glucose control in trials. 3. The drug targets metabolic dysfunction-associated steatohepatitis and type 2 diabetes. 4. Clinical-stage focus positions MetaVia in the growing biotechnology market. 5. Good tolerance in earlier trials suggests potential for further development.

6m saved
Insight
Article

FAQ

Why Bullish?

The acceptance of DA-1241's trial data for presentation indicates positive momentum. Historical cases show that similar announcements usually enhance investor confidence and stock prices.

How important is it?

The article highlights significant clinical advancements that could reshape MetaVia's market standing, elevating investor interest in the long term.

Why Long Term?

Results presented in conferences can influence future investments and partnerships. As the efficacy of DA-1241 is validated, it could lead to market traction and revenue generation.

Related Companies

NANVRTXREGN
, /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), has been accepted as a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place May 7-10, 2025 in Amsterdam, the Netherlands. Title: DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients Presenting Author: Rohit Loomba, MD, MHSc, Professor of Medicine in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at University of California, San Diego. Abstract Number: LB2517 Final Abstract ID: LBP-005 Session: Late Breaker Posters Session Date: May 7-10, 2025 Presentation Start: May 7, 2025, 8:30 am CET A copy of the poster will be available on the Posters section of the MetaVia website after the presentation. About DA-1241DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects. About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects. For more information, please visit www.metaviatx.com. Contacts: MetaViaMarshall H. WoodworthChief Financial Officer+1-857-299-1033[email protected] Rx Communications GroupMichael Miller+1-917-633-6086[email protected] SOURCE MetaVia Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News